Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guofeng Cheng

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
ACS Medicinal Chemistry Letters|April 17, 2024
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873Darryl Kato, Regina Wai-Yan Choy, Eda Canales, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV InhibitorsScott E Lazerwith, Gina Bahador, Eda Canales, et al.
Antimicrobial Agents and Chemotherapy|January 15, 2014
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrugJoy Y Feng, Guofeng Cheng, Jason Perry, et al.
JCI Insight|April 8, 2024
Prophylactic efficacy of an intranasal spray with 2 synergetic antibodies neutralizing OmicronXinghai Zhang, Feiyang Luo, Huajun Zhang, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
ACS Medicinal Chemistry Letters|April 17, 2024
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873Darryl Kato, Regina Wai-Yan Choy, Eda Canales, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV InhibitorsScott E Lazerwith, Gina Bahador, Eda Canales, et al.
Antimicrobial Agents and Chemotherapy|January 15, 2014
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrugJoy Y Feng, Guofeng Cheng, Jason Perry, et al.
JCI Insight|April 8, 2024
Prophylactic efficacy of an intranasal spray with 2 synergetic antibodies neutralizing OmicronXinghai Zhang, Feiyang Luo, Huajun Zhang, et al.
Pageof 14